Phase 2 N=36 KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Gastric Cancer · Esophagus Cancer
Primary: Months of Progression-free Survival (PFS) — 7.6 months — p=0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty
Postoperative Recovery
Primary: Effect of GRF6021 on Immune Responses to Surgery as Determined by Cytometry by Time of Flight (CyTOF) on Day 2 — 0.5692; 0.4521; 0.5326; 0.4471 predicted value
Phase 1 N=16 This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5931.13; 3871.50…
N/A N=14 Managing Cancer and Living Meaningfully
Mood · Cancer Brain
Primary: Recruitment for CALM — 14; 14; 12 Participants
N/A N=68 Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence
Nicotine · Vaping · Nicotine Vaping
Primary: 3-HPMA — 657.46; 726.84; 703.29; 724.06 ng/mg creatinine
N/A N=40 A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia · Persistent Atrial Fibrillation · Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Pre-ablation Mapping Requirements and Clinically Indicated Mapping Performed With the Investigational Catheter Without Resort to Non-study…
N/A N=45 The BRAIN App: Building Relationships Using Artificial Intelligence and Nostalgia
Dementia · Dementia, Vascular · Alzheimer Disease
Primary: Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale — .72 score on scale — p=<0.01
Phase 2 N=30 Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
Allogeneic Hematopoietic Stem Cell Transplantation Recipient · Osteopenia · Osteoporosis
Primary: Mean Total Hip Percent Change in Bone Mineral Density (BMD) — -4.28 percent change
N/A N=151 Optimal Feeding Tube Dwell Time in VLBW Infants to Reduce Feeding Tube Contamination
Infection
Primary: Amount of Contamination — 357,000,000; 4,820,000,000 Colony forming units
N/A N=64 Effects of Open-label Placebos on COVID-related Psychological Health
Stress · Anxiety · Depression
Primary: COVID-19 Related Stress — 34.93; 35.13; 26.24; 32.37 score on a scale
Phase 4 N=58 Comparison of Time to Extubation Using Sugammadex or Neostigmine
Neuromuscular Blockade · Chronic Obstructive Pulmonary Disease
Primary: Number of Minutes to Return of Baseline Muscle Tone — 3.9; 12.9 minutes
Phase 2 N=58 Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
Diffuse Large B-Cell Lymphoma Unclassifiable
Primary: Overall Response Rate — 86.2 percentage of participants
N/A N=111 OPTIMAL in NH Residents With Dementia
Alzheimer's Disease and Related Dementias
Primary: Number of Staff Participants Who Viewed the Intervention as Appropriate and Acceptable for Mealtime Care Practice — 94 Participants
Phase 2 N=160 Study of ST-100 as Treatment for Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline of Total Corneal Fluorescein Staining (Ora Calibra® Scale) in the Study Eye at Visit 7 (Day 29) Pre-Controlled Adverse Environment (Pre-CAE)…
Phase 3 N=57 Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
PTSD · Alcohol Use Disorder
Primary: Heavy Drinking Days as Measured by the Time Line Follow Back (TLFB) — 10.5; 10.2; 1.1; 1.0 days — p=0.80